Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy.

Based on these exploratory data, a rise in plasma ALP might indicate disease progression and should be interpreted cautiously during therapy.